doi: 10.1016/j.pmpp.2008.04.003 43 LiX.AnM.XiaZ.BaiX.WuY
Both are GLP-1 receptor agonists that treat type 2 diabetes and reduce cardiovascular risk, but they differ in molecule and dosing frequency
Risk of Legal Blindness and Ischemic Optic Neuropathy The GLP-1 cohort had a statistically significant reduction in risk of legal blindness, at all measured time periods, as compared to the control, with a 1-year hazard ratio of 0.589 (95% CI: 0.4760.728), 3-year HR of 0.677 (95% CI: 0.5830.788), and 5-year HR of 0.669 (95% CI: 0.5830.768)
AMP-activated protein kinase signaling is upregulated in papillary thyroid cancer
Always consult your healthcare provider before starting, switching, or stopping any medication
The critical difference is how many receptors each drug activates